Windlas Biotech Limited
The price is rich while the print and outlook don't fully back it — you're paying ahead of what the legs show.
Overall read
5.8/10
Priced ahead of it
The three reads · this quarter
The price is rich while the print and outlook don't fully back it — you're paying ahead of what the legs show.
Overall read
5.8/10
Priced ahead of it
The three reads · this quarter
The price is rich while the print and outlook don't fully back it — you're paying ahead of what the legs show.
Overall read
5.8/10
Priced ahead of it
The three reads · this quarter
The standing reads · change less often
Moat
No moat read published yet.
Key variables
No key-variables snapshot yet.
Walk the talk
Not enough tracked guidance to grade yet.
Plant 6 commercialization in H1 FY27 to add significant capacity, targeting INR 1,000 crore revenue potential.
Where it sits